AVITA Medical, Inc. (RCEL): Entry into a Material Definitive Agreement
AVITA Medical, Inc. (RCEL) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-4.1 2 rcel-ex4_1.htm EX-4.1 EX-4.1 Exhibit 4.1 WARRANT certificate THIS WARRANT certificate HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ SECURITIES ACT ”), OR QUALIFIED UNDER ANY STATE OR FOREIGN SECURITIES LAWS AND MAY NOT BE OFFERED FOR SALE, S
How this was made
The 30-second read
Why it matters
The disclosed warrant grants the holder the right to purchase up to 650,000 shares, which can increase future share count if exercised; it also ties the company’s capital structure to the credit facility’s terms.
Market read
A new warrant issuance under an existing credit facility is disclosed, which can affect valuation via dilution/financing risk and may influence trading around capital-structure headlines.
What to watch
Traders should focus on the missing economic terms (exercise price, vesting/exercise conditions, and any cashless exercise/cancellation mechanics) to gauge real dilution and timing of potential share issuance.
Background
The filing is an SEC 8-K describing entry into a material definitive agreement and includes an exhibit warrant certificate issued under a January 13, 2026 Credit and Guaranty Agreement.
Ticker impact
AVITA Medical entered a material definitive agreement and issued a warrant certificate for up to 650,000 common shares to Perceptive Credit.
Near-term bias likely neutral-to-negative due to dilution/optionality, with direction depending on warrant terms (exercise price/conditions) not fully shown in the excerpt.
This is a primary SEC filing (8-K) with a concrete new security issuance (warrants up to 650,000 shares). However, the excerpt does not provide the exercise price or key economic terms, limiting precision on dilution magnitude and immediate valuation impact.
Market effects
Signals continued reliance on credit-linked equity warrants in the medtech/healthcare financing ecosystem.
No clear regional spillover indicated.
No explicit global linkage beyond standard warrant/credit agreement mechanics.
Counterpoint
If the warrant exercise price is sufficiently high or the holder’s exercise is conditional/limited, the overhang may be smaller than typical warrant fears.
Key entities
- issuerAVITA Medical, Inc.
Company filing the 8-K and issuing the warrant certificate.
- lender/holderPerceptive Credit Holdings V, LP
Warrant holder entitled to purchase up to 650,000 shares under the certificate.
- lenderPerceptive Credit Opportunities Fund V, LP
Named as the lender in the January 13, 2026 Credit Agreement.
